Semin Hematol. 2013 Apr;50(2):175-84. doi: 10.1053/j.seminhematol.2013.03.023.
Animal models of hemophilia and related diseases are important for the development of novel treatments and to understand the pathophysiology of bleeding disorders in humans. Testing in animals with the equivalent human disorder provides informed estimates of doses and measures of efficacy, which aids in design of human trials. Many models of hemophilia A, hemophilia B, and von Willebrand disease (VWD) have been developed from animals with spontaneous mutations (hemophilia A dogs, rats, sheep; hemophilia B dogs; and VWD pigs and dogs), or by targeted gene disruption in mice to create hemophilia A, B, or VWD models. Animal models have been used to generate new insights into the pathophysiology of each bleeding disorder and also to perform preclinical assessments of standard protein replacement therapies, as well as novel gene transfer technology. The differences both between species and in underlying causative mutations must be considered in choosing the best animal for a specific scientific study.
动物模型在血友病和相关疾病的研究中具有重要意义,它们有助于开发新的治疗方法,并深入了解人类出血性疾病的病理生理学。在具有人类同等疾病的动物身上进行测试,可以提供关于剂量和疗效的明智估计,有助于设计人体临床试验。许多自发性突变动物(血友病 A 犬、大鼠、绵羊;血友病 B 犬;以及血管性血友病猪和犬)或通过基因靶向敲除技术在小鼠中创建的血友病 A、B 或 VWD 模型,都被用于开发血友病 A、B 和血管性血友病(von Willebrand disease,VWD)的动物模型。这些动物模型被用于深入了解每种出血性疾病的病理生理学,也用于标准蛋白替代疗法以及新型基因转移技术的临床前评估。在选择最适合特定科学研究的动物时,必须考虑物种间和潜在致病突变的差异。